Results 201 to 210 of about 188,184 (297)

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence

British Journal of Haematology, EarlyView.
Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco, Patrick Harrington, Elena Torre, Hillary Catellani, Novella Pugliese, Matteo Pacilli, Annalisa Santisi, Arianna Sbriglione, Giuseppe A. Palumbo   +8 more
wiley   +1 more source

Factors Influencing Unplanned Discontinuation of Continuous Renal Replacement Therapy: A Descriptive Time-Series Analysis. [PDF]

Nurs Crit Care
Jia W, Xu H, Peng R, Wang H, Lu H, Bi Y.
europepmc   +1 more source

A pro‐inflammatory cytokine signature characterises thrombotic antiphospholipid syndrome despite stable anticoagulation

British Journal of Haematology, EarlyView.
Primary antiphospholipid syndrome comprises distinct inflammatory subgroups defined by cytokine profiling. A shared pro‐inflammatory signature is present across all patients, whereas arterial thrombosis demonstrates enhanced inflammatory activation compared with venous thrombosis, suggesting divergent pathogenic mechanisms and opportunities for ...
Catherine B. Ducker, Megan V. Preece, Jeremy Schofield, Charis Pericleous, Mike Laffan, Simon Abrams, Deepa J. Arachchillage   +6 more
wiley   +1 more source

Catheterisation after urethral lengthening in transgender/gender‐diverse individuals: a randomised controlled trial (Safe Access for Bladder Entry in Transgender Men Following Penile Reconstruction [SAFE])

BJU International, EarlyView.
Objective To conduct a randomised controlled trial (RCT) to assess the efficacy of the Urethrotech urethral catheterisation device (UCD®; Urethrotech Ltd., Kingston Upon Thames, Surrey, UK) catheter compared to a standard Foley catheter for catheterisation in post‐phalloplasty transgender and gender diverse (TGD) individuals following urethral ...
Anastasia Frost, Andrea Gobbo, Nim Christopher, David Ralph, Wai Gin Lee   +4 more
wiley   +1 more source

Rivaroxaban as Secondary Thromboprophylaxis in Pediatric Patients With Short Bowel Syndrome. [PDF]

Case Rep Hematol
Journell AF, Peters CE, Meznarich J, Goteti S.   +3 more
europepmc   +1 more source

Aquablation as salvage therapy for benign prostatic hyperplasia: an international multicentre study

BJU International, EarlyView.
Objective Our objective was to evaluate the safety and effectiveness of Aquablation® as a salvage therapy in patients who underwent prior intervention for benign prostatic hyperplasia (BPH). Materials and Methods We retrospectively analysed 1887 consecutive men from the International Collaborative Aquablation Research Urology Society database between ...
Anouk Leathead, Nick Lee, Adel Arezki, David Bouhadana, Liam Murad, Tarek Benzouak, Iman Sadri, Rosie Foucault, Aalya Hamouda, Jeffrey Sioufi, Ilan Ohana, Joshua Cabral, Margaret Gannon, Gregory Raster, David Nusbaum, Abdulla Alameeri, John Klein, Inderjit Singh, James Kearns, Shawn Marhamati, Alexander Glaser, Brian Helfand, Dean Elterman, Tiago Rodrigues, Kevin C. Zorn   +24 more
wiley   +1 more source

Efficacy and safety of anticoagulation for pediatric cerebral sinovenous thrombosis: systematic review and meta-analysis. [PDF]

Res Pract Thromb Haemost
Azzam M, Kawtharany H, Betensky M, Alkhader A, Hamarsha Q, Abou Zeid HK, Mansour R, Tabak C, Patel P, Baghdadi SL, Bercovitz RS, Bhat R, Biss T, Branchford BR, Brandão LR, Chan AKC, Faustino EVS, Jaffray J, Jones S, Kerlin BA, Kucine N, Kumar R, Male C, Pelland-Marcotte MC, Raffini L, Raulji CM, Sartain SE, Takemoto CM, Tarango C, Van Ommen CH, Velez MC, Vesely SK, Wiernikowski J, Williams S, Wilson HP, Woods G, Zia A, Monagle P, Mustafa RA.   +38 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source